ADIM
EOLS icon

Alpha DNA Investment Management’s Evolus EOLS Stock Holding History

Alpha DNA Investment Management’s Portfolio EOLS Stock Details EOLS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-35,562
Closed -$498K – 217
2024
Q1 		$498K Buy
+35,562
New +$462K 0.18% 155

Other funds holding EOLS

PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return
CP
Caligan Partners New York $1.5B AUM 518.95% 1-Year Est. Return
SCM
Stonepine Capital Management Bend, Oregon $250M AUM 77.6% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Alpha DNA Investment Management's EOLS Position: Q2 2024 in Review

Alpha DNA Investment Management sold out of Evolus (EOLS) in Q2 2024, closing a stake of 35,562 shares — an estimated $498K sold.

Alpha DNA Investment Management first reported a position in EOLS in Q1 2024 and held it in 1 quarter. The position peaked at $498K in Q1 2024. 156 funds tracked by Wall St. Rank hold EOLS as of Q2 2024.

  • Alpha DNA Investment Management reported no remaining Evolus position as of Q2 2024 after selling out during the quarter.
  • Alpha DNA Investment Management sold 35,562 Evolus shares in Q2 2024, an estimated $498K.
  • Alpha DNA Investment Management first reported a position in Evolus in Q1 2024 and held it in 1 quarter.
  • Alpha DNA Investment Management's Evolus position peaked at $498K in Q1 2024.
  • 156 funds tracked by Wall St. Rank held Evolus as of Q2 2024.

Based on Alpha DNA Investment Management's 13F filing for Q2 2024, filed 14 Aug 2024.